Sphenopalatine Ganglion Block in Septorhinoplasty

Completed

• Conditions: Pain, Postoperative; Rhinoplasty

• Registration Number: NCT06157970
• Lead Sponsor: Istanbul Medeniyet University

Brief Summary

Septorhinoplasty is a widely performed surgery that aims to correct both functional and aesthetic problems of the nose. Despite its expected clinical benefits, septorhinoplasty surgery causes postoperative pain, which affects the patient's functional recovery and satisfaction. Opioids, Non-steroidal anti-inflammatory drugs (NSAII), acetaminophen and local anesthetics are used in peroperative pain management in septorhinoplasty. Sphenopalatine ganglion block (SPGB), which has been recently described and has different application areas, is a regional analgesia technique that has been investigated for this purpose. Although there are studies on postoperative pain in septorhinoplasty surgeries, there are not enough studies on its effects on intraoperative pain.

This study may have positive effects on appropriate pain management, patient comfort and surgical outcomes as multimodal analgesia management in septorhinoplasty surgeries, and may make significant contributions to evidence-based practices.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-07
• Primary Completion: 2023-08-21
• Study Completion: 2023-08-21
• Study First Submitted: 2023-11-08
• Status Verified: 2023-12
• Study First Submitted QC: 2023-12-04
• Last Update Submitted: 2023-12-04
• Study First Posted: 2023-12-06
• Last Update Posted: 2023-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Undergoing septorhinoplasty surgery
• Ages between 18-65
• ASA (American Society of Anesthesiologists) score I-II

Exclusion Criteria

• Unavailable postoperative pain scores and analgesic use in the hospital registry system
• Local anesthetic drug allergy and toxicity
• Advanced organ failure
• Mental retardation

Patients who are pregnant

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
remifentanil consumption	2 hours	microgram

Secondary Outcome Measures

Name	Time	Method
Numerical Rating Scale	15 minute, 30 minute, 1hour, 2 hour, 4 hour, 8 hour,16 hour, 24 hour	Minimum values=1 and Maximum value=10. Highest values are worse outcome.

Trial Locations

Locations (1)

Suheda Akbulut; 🇹🇷 Istanbul, Turkey